Tysabri Risk Redux: Additional PML Cases Create REMS Challenge For FDA

The emergence of two new cases of progressive multifocal leukoencephalopathy linked to Biogen Idec/Elan's Tysabri (natalizumab) comes just before the deadline for the firms to submit a formal Risk Evaluation and Mitigation Strategy for the product, and while FDA is still experimenting with how to apply its new REMS authorities

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet